Javascript must be enabled to continue!
Recent Advances in Gelatin-Based Nanomedicine for Targeted Delivery of Anti-Cancer Drugs
View through CrossRef
:
Nanoparticles based on natural polymers are utilized for the development of a wide range of drug delivery
systems (DDS) in the current era. Gelatin-based nanoparticles, for example, are a remarkable cancer therapy
with high efficacy and specificity. This paper reviews the recent advancements in gelatin-based
nanomedicine for use in cancer therapeutics. Due to the characteristics features of gelatin, such as biocompatibility,
biodegradability, stability, and good surface properties, these nanoparticles provide high therapeutic potency
in cancer nanomedicine. The surface of gelatin can be modified in a number of ways using various ligands
to explore the platform for the development of a more novel DDS. Various methods are available for the
preparation of gelatin nanomedicine discussed in this review. In addition, various cross-linkers to stabilized
nanocarriers and stimuli base gelatin nanoparticles are reviewed. Furthermore, recent advances and research in
gelatin-based nanomedicine are discussed. Also, some drawbacks and challenges are evaluated. In general, this
paper paves the pathway to identify the details about the gelatin-based DDS for cancer therapy.
Bentham Science Publishers Ltd.
Title: Recent Advances in Gelatin-Based Nanomedicine for Targeted Delivery of Anti-Cancer Drugs
Description:
:
Nanoparticles based on natural polymers are utilized for the development of a wide range of drug delivery
systems (DDS) in the current era.
Gelatin-based nanoparticles, for example, are a remarkable cancer therapy
with high efficacy and specificity.
This paper reviews the recent advancements in gelatin-based
nanomedicine for use in cancer therapeutics.
Due to the characteristics features of gelatin, such as biocompatibility,
biodegradability, stability, and good surface properties, these nanoparticles provide high therapeutic potency
in cancer nanomedicine.
The surface of gelatin can be modified in a number of ways using various ligands
to explore the platform for the development of a more novel DDS.
Various methods are available for the
preparation of gelatin nanomedicine discussed in this review.
In addition, various cross-linkers to stabilized
nanocarriers and stimuli base gelatin nanoparticles are reviewed.
Furthermore, recent advances and research in
gelatin-based nanomedicine are discussed.
Also, some drawbacks and challenges are evaluated.
In general, this
paper paves the pathway to identify the details about the gelatin-based DDS for cancer therapy.
Related Results
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract
Introduction
Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
The Promise of Exosomes as Drug Delivery Systems
The Promise of Exosomes as Drug Delivery Systems
Exosomes are small extracellular vesicles that play a role in cell-to-cell communication by transferring bioactive molecules such as proteins, nucleic acids, and lipids between cel...
Abstract PO-040: Integration of anti-TIGIT and anti-Lag3 with NBTXR3-mediated immunoradiation therapy improves abscopal effect and induces long-term memory against cancer
Abstract PO-040: Integration of anti-TIGIT and anti-Lag3 with NBTXR3-mediated immunoradiation therapy improves abscopal effect and induces long-term memory against cancer
Abstract
Introduction: TIGIT and Lag3 are inhibitory receptors expressed on cytotoxic CD8+ T cells and NK cells and directly inhibit the activation and proliferation...
Autoantibody Profile in Systemic Lupus Erythematosus Patients
Autoantibody Profile in Systemic Lupus Erythematosus Patients
AbstractSystemic lupus erythematosus (SLE) is an autoimmune disease, in which the etiology is not well-understood; however, interactions between environmental and genetic factors i...
Determinants of stock-outs of first line anti-tuberculosis drugs: the case of public health facilities of Addis Ababa city administration health bureau, Addis Ababa, Ethiopia
Determinants of stock-outs of first line anti-tuberculosis drugs: the case of public health facilities of Addis Ababa city administration health bureau, Addis Ababa, Ethiopia
Abstract
Background
The health sectors success has been determined by consistent and reasonably priced health commodities supply. Despite possible d...
Abstract OI-1: OI-1 Decoding breast cancer predisposition genes
Abstract OI-1: OI-1 Decoding breast cancer predisposition genes
Abstract
Women with one or more first-degree female relatives with a history of breast cancer have a two-fold increased risk of developing breast cancer. This risk i...
11 Years of CLINAM, the European Foundation for Clinical Nanomedicine
11 Years of CLINAM, the European Foundation for Clinical Nanomedicine
CLINAM is a nonprofit organization based in Basel, Switzerland (www.clinam.org), that has been founded by Beat Löffler and Patrick Hunziker in 2007. The organization, utilizing its...

